Skip to content
MondayNightIBD | IL-23p19 Therapies in IBD Tweetorial
March 10, 2025 ~ Aline Charabaty, MD
**Pre-assessment**
Before you participate in this activity, please take this pre-assessment.
Taking this pre-assessment does not immediately qualify learners to earn credit.
Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
*
1.
Where are you in your career?
(Required.)
IBD Specialist
General GI
Fellow/Trainee
APP
PharmD
Other (please specify)
*
2.
32 w new dx of Crohns colitis plan to start anti-IL23p19 Miri. You discuss the importance of endo improvement on therapy in addition to clinical remission.
What is the % of pts who had endo response at 1 yr on Miri & who continue to have endo improvement at year 2 of therapy?
(Required.)
20-30
40-50
60-70
80-90
*
3.
25 y/o with moderate UC is considering treatment options and is very concerned about risks of therapies in partic risk of infection & lymphoma.
Which MOAs do you present as having a good ⚖️ of efficacy and safety profile?
(Required.)
Anti-TNF + AZA
JAKi
AZA
Anti-integrin & anti-IL23
4.
Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.
First & Last Name
🔗
Proceed to activity on X/MondayNightIBD
🔗 Proceed to activity post-survey
(post-survey completion must occur on or after activity launch date and prior to activity expiration date to be valid for claiming credit)
